Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Neuronetics, Inc.NASDAQ: STIM

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -$15.17M, compared with $1.77M a year earlier. Trailing-twelve-month net change in cash was -$2.26M.

Context

  • Net change in cash amounted to 9.8% of revenue in FY2025, down 43.9 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$15.17M or moves back toward the trailing-twelve-month quarterly average of -$565K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$15.17M+4401.5% QoQ
Last fiscal yearDec 2025
$14.68M+136.5% YoY
LTMMar 2026
-$2.26M-91.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-959.5%——
1 year+136.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
14.68M USD
Year-over-year change
+136.5%
4-year CAGR
-24.5%

Net Change in Cash vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -91.5% is the 7th highest of 9, against a peer median of +48.5%.
  • Net change in cash amounts to 1.5% of revenue for STIM, versus a peer median of 30.3%.
STIM Competitors
Net Change in Cash for STIM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSUROraSure Technologies, Inc.LTM Mar 2026$70.61M USD-16752.1%-87.2%62.5%
CDXSCodexis, Inc.LTM Mar 2026$23.69M USD+159.6%—30.3%
PREPrenetics Global LimitedLTM Mar 2026$21.32M USD——18.7%
OABIOmniAb, Inc.LTM Mar 2026$18.15M USD+322.3%—62.8%
NYXHNyxoah S.A.LTM Mar 2026€10.02M EUR-3261.2%-89.6%61.4%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$9.57M USD+109.8%—1547.9%
PROFProfound Medical Corp.LTM Mar 2026$3.75M USD-28.6%—19.9%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$2.41M USD+108.4%-34.1%7.0%
STIMNeuronetics, Inc.LTM Mar 2026$2.26M USD-91.5%—1.5%
ATLNAtlantic International Corp.LTM Dec 2025$597.54K USD-11.4%-31.2%0.1%
Peer median (excluding STIM) —+48.5%-60.6%30.3%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.19M)(37.16M)(30.19M)(43.73M)(39.14M)
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
Deferred Income Tax00000
Stock-Based Compensation7.87M8.75M7.32M5.6M6.85M
Change in Working Capital(6.64M)(5.12M)(14.1M)(6.81M)6.58M
Accounts Receivables(3.05M)(6.66M)(8.83M)(3.73M)3.54M
Inventory(3.44M)(2.59M)(1.1M)3.15M(395K)
Accounts Payables276K(1.97M)2.03M(1.99M)(1.75M)
Other Working Capital(415K)6.1M(6.2M)(4.25M)5.18M
Other Non-Cash Items918K1.14M2.93M11.86M1.87M
Operating Cash Flow(27.98M)(30.74M)(32.04M)(31M)(20.37M)
Capital Expenditures(2.35M)(3.27M)(2.37M)(1.47M)(801K)
Acquisitions (Net)000(2.55M)0
Purchases of Investments00000
Sales of Investments324K000(31K)
Other Investing Activities(7.81M)10M1.05M1.61M31K
Investing Cash Flow(9.84M)6.73M(1.32M)(2.41M)(801K)
Debt Repayment0023.8M(2.52M)9.62M
Common Stock Issued80.97M00026.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.03M207K(1.1M)(4.29M)(594K)
Financing Cash Flow83.01M207K22.7M(6.81M)35.85M
Effect of Forex Changes00000
Net Change in Cash45.18M(23.8M)(10.66M)(40.22M)14.68M
Free Cash Flow(30.34M)(34.01M)(34.41M)(32.46M)(21.18M)

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.